FDAnews Device Daily Bulletin
Medical Devices / Submissions and Approvals

HiberGene Earns CE Mark for Rapid Flu Test

Dec. 17, 2018
A A

HiberGene Diagnostics, a developer of rapid molecular tests for human infectious diseases, earned the CE Mark for its HG Flu A / B Combo test.

 The rapid molecular test uses nasopharyngeal swabs for the direct detection of the influenza virus and can differentiate between the A and B subtypes to facilitate best treatment options.

The test can be performed on the company’s HG Swift analyser, to test four samples simultaneously and provide results in approximately 30 minutes.

HiberGene has launched the new flu test in Europe, Asia and South America.

View today's stories